The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of BIM and mTOR expression on clinical outcome to erlotinib in EGFR-mutant non-small cell lung cancer (NSCLC) patients (p).
Niki Karachaliou
No relevant relationships to disclose
Ana Drozdowskyj
No relevant relationships to disclose
Ana Gimenez Capitan
No relevant relationships to disclose
Andres Felipe Cardona Zorrilla
No relevant relationships to disclose
Radj Gervais
No relevant relationships to disclose
Bartomeu Massuti
No relevant relationships to disclose
Teresa Moran
No relevant relationships to disclose
Margarita Majem
No relevant relationships to disclose
Enriqueta Felip
No relevant relationships to disclose
Enric Carcereny Costa
No relevant relationships to disclose
Rosario Garcia Campelo
No relevant relationships to disclose
Santiago Viteri Ramirez
No relevant relationships to disclose
Daniela Morales-Espinosa
No relevant relationships to disclose
Alberto Verlicchi
No relevant relationships to disclose
Elisabetta Crisetti
No relevant relationships to disclose
Imane Chaib
No relevant relationships to disclose
Jose Luis Ramirez
No relevant relationships to disclose
Patrick C. Ma
No relevant relationships to disclose
Rafael Rosell
No relevant relationships to disclose